Is Mobotinib (Mobosetinib) available in China?

Mobocertinib (Mobocertinib) is an oral tyrosine kinase inhibitor (TKI) mainly used to treat non-small cell lung cancer (NSCLC). The drug targets the epidermal growth factor receptor (EGFR) exon 20 insertion mutation, inhibits the signaling pathway activated by the EGFR mutation, thereby inhibiting the growth and proliferation of cancer cells.

Mobotinib (Mobosetinib) is currently on the market in China, but it is not included in medical insurance. It is difficult to purchase Mobotinib (Mobosetinib) in China. For specific information, please consult the local hospital pharmacy. There are original drugs and generic drugs abroad. The original drugs include the Hong Kong version of Japan's Takeda original drug, which costs about 7,000 to 8,000 yuan. The generic drugs are mainly generic drugs from Laos and Bangladesh, which cost more than 3,000 yuan, which is about half cheaper than the original drug. The ingredients of the drugs are basically the same.

The primary indication for mobosetinib is for patients with advanced or metastatic NSCLC who have previously received platinum-containing chemotherapy and have EGFR exon 20 insertion mutations. The drug fills a treatment gap for patients with this specific mutation, whose mutational characteristics make conventional EGFR-TKI therapies (such as erlotinib, gefitinib, etc.) ineffective. In 2021, mobotinib (mobosetinib) received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of such patients.

Common side effects of mobosetinib include diarrhea, rash, mouth sores, loss of appetite, and nausea. During treatment, the patient's cardiac function needs to be closely monitored as the drug may cause cardiac-related adverse reactions such as QT prolongation. In addition, abnormal liver function is also a potential risk that needs attention.

In clinical use, Mobotinib (mobosetinib) is usually taken once daily and is not affected by food. Due to its many side effects, doctors will adjust the dosage according to the patient's tolerance and condition during medication. In addition, since the metabolism of this drug is mainly throughCYP3A4Enzyme system is used, so attention should be paid to drug-drug interactions and avoid simultaneous use with strong inhibitors or inducers of CYP3A4.